AFFY

AFFYMAX INC

A biopharmaceutical company that developed Omontys, a once-monthly injectable drug for anemia in kidney-dialysis patients. Born in 2001 when drug giant GlaxoSmithKline spun off its Affymax research unit, the company later recalled Omontys in 2013 over allergic reactions and eventually stopped developing new drugs. Its name blends "affinity" with "max" — a nod to the peptide chemistry used to find molecules that bind tightly to their targets.

No 8-K or 6-K filings recorded.